| Management target | Revenue 11.0% 2034E |
|---|
| Revenue growth | 17% YoY |
|---|---|
| Margins | EBITDA margin expanded 210 bps to 25.2%. |
| Demand visibility | Sustained momentum in specialty and wellness segments. |
| Management confidence | High; outperforming growth guidance due to network expansion. |
Growth
Revenue grew 17% YoY; PAT increased 26% to INR 57 Cr; Patient and test volumes grew 10% and 11% respectively.
Outlook
Metropolis 3.0 strategy focuses on AI, genomics, and Tier-3+ expansion; network includes 209 labs and 5,000+ service points.
Risks
Highly fragmented market (85% unorganised/hospital-based); continued competition from digital and chain-based diagnostic players.
Last quarter's promises, checked
Delivered
- Organic revenue growth 12-13% → delivered 13.7% (= BEAT)
- Core Diagnostics EBITDA -2% to high-single-digit → delivered high-single-digit (= BEAT)
- Expand presence to 750+ towns → delivered 750+ towns (= BEAT)
Partly delivered
- EBITDA margin 125-150 bps improvement → delivered 210 bps (= BEAT but current call is Q1 vs FY guidance)
Investor Presentation filed with BSE, NSE: METROPOLIS. Summary written with AI assistance from the document.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹582.60
- Market cap
- ₹12,086 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 59.9×Sector 57.8×
- Promoter holding
- 48.86%-0.01% QoQ
- FII holding
- 11.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Employee Stock Options
Metropolis Healthcare allotted 66,312 equity shares to employees under its RSU Plan, 2020. This exercise follows the vesting of RSUs previously granted to staff.
Metropolis Healthcare Merger & Restructuring Worth ₹1.26 Cr
Metropolis Healthcare's subsidiary MQSPL will issue shares to Medsource and Dr. Puneet Kumar Nigam for ₹1.26 Crore, diluting MHL's stake to 54.90% through this strategic restructuring.
- Value
- ₹1.26 Cr
Metropolis Healthcare Capital Structure Change
Franklin Templeton Mutual Fund acquired 7,42,409 Metropolis Healthcare shares via open market, raising its stake to 5.10%. No transaction value was disclosed in the filing.
Metropolis Healthcare Earnings Call Transcript: Key Takeaways
Metropolis Healthcare reports a strong Q1FY27, beating its own revenue guidance through volume-led growth and aggressive tier-2/3 expansion.
- Call
- Guides 15% growth
Metropolis Healthcare Q1 FY27 Results: Net Profit ₹56.9 Cr, Up 25.9% YoY
Metropolis Healthcare Ltd reported revenue from operations of ₹450.2 Cr (+16.6% YoY) and net profit of ₹56.9 Cr (+25.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹56.9 Cr · +25.9% YoY
Metropolis Healthcare Earnings Call: Key Takeaways
Metropolis Healthcare reports strong FY26 performance with 23.6% YoY revenue growth and 24.4% EBITDA margin. Strategy focuses on network productivity, genomics, and expanding 'mini hubs' for pathology and basic radiology.